Browsing Tag
ProKidney Corp.
2 posts
Can rilparencel’s eGFR gains in Group 1 justify accelerated FDA approval for ProKidney in 2025?
ProKidney’s rilparencel showed a 78% improvement in eGFR slope—can this surrogate endpoint clear the way for FDA fast-track approval in 2025?
ProKidney (NASDAQ: PROK) stock surges over 22% after Phase 2 REGEN-007 trial shows strong kidney function stabilization
Find out why ProKidney stock soared 22% after new Phase 2 data on rilparencel in chronic kidney disease patients. Analysts see potential FDA fast-track.